- Home
- BBUC vs IBRX Comparison
BBUC vs IBRX Comparison
Compare BBUC & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBUC
- IBRX
- Stock Information
- Founded
- BBUC 2022
- IBRX 2014
- Country
- BBUC United States
- IBRX United States
- Employees
- BBUC N/A
- IBRX N/A
- Industry
- BBUC
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BBUC
- IBRX Health Care
- Exchange
- BBUC Nasdaq
- IBRX Nasdaq
- Market Cap
- BBUC 2.4B
- IBRX 2.3B
- IPO Year
- BBUC N/A
- IBRX N/A
- Fundamental
- Price
- BBUC $34.59
- IBRX $2.90
- Analyst Decision
- BBUC
- IBRX Strong Buy
- Analyst Count
- BBUC 0
- IBRX 6
- Target Price
- BBUC N/A
- IBRX $9.83
- AVG Volume (30 Days)
- BBUC 92.1K
- IBRX 9.8M
- Earning Date
- BBUC 11-01-2025
- IBRX 11-11-2025
- Dividend Yield
- BBUC 0.73%
- IBRX N/A
- EPS Growth
- BBUC N/A
- IBRX N/A
- EPS
- BBUC N/A
- IBRX N/A
- Revenue
- BBUC $8,240,000,000.00
- IBRX $56,600,000.00
- Revenue This Year
- BBUC N/A
- IBRX $629.94
- Revenue Next Year
- BBUC N/A
- IBRX $109.91
- P/E Ratio
- BBUC N/A
- IBRX N/A
- Revenue Growth
- BBUC 6.96
- IBRX 4227.22
- 52 Week Low
- BBUC $21.52
- IBRX $1.83
- 52 Week High
- BBUC $35.19
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- BBUC 58.07
- IBRX 72.78
- Support Level
- BBUC $33.56
- IBRX $2.32
- Resistance Level
- BBUC $34.58
- IBRX $2.67
- Average True Range (ATR)
- BBUC 1.01
- IBRX 0.14
- MACD
- BBUC -0.05
- IBRX 0.07
- Stochastic Oscillator
- BBUC 74.09
- IBRX 99.23
About BBUC Brookfield Business Corporation Exchangeable Subordinate Voting Shares
Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a world-wide basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.